Skip to content
Vumerity(diroximel fumarate)
Vumerity (diroximel fumarate) is a small molecule pharmaceutical. Diroximel fumarate was first approved as Vumerity on 2019-10-29. It is used to treat relapsing-remitting multiple sclerosis in the USA. It has been approved in Europe to treat relapsing-remitting multiple sclerosis.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
nervous system diseasesD009422
immune system diseasesD007154
Trade Name
FDA
EMA
Vumerity
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Diroximel fumarate
Tradename
Company
Number
Date
Products
VUMERITYBiogenN-211855 RX2019-10-29
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
vumerityNew Drug Application2022-09-30
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
relapsing-remitting multiple sclerosisEFO_0003929D020529—
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Diroximel Fumarate, Vumerity, Biogen Inc
86692812033-09-20DS, DP
90905582033-09-20U-1384
100807332033-09-20DS, DPU-1384
ATC Codes
L: Antineoplastic and immunomodulating agents
— L04: Immunosuppressants
— L04A: Immunosuppressants
— L04AX: Other immunosuppressants in atc
— L04AX09: Diroximel fumarate
HCPCS
No data
Clinical
Clinical Trials
11 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Multiple sclerosisD009103EFO_0003885G35——2—35
Relapsing-remitting multiple sclerosisD020529EFO_00039291—1——2
Indications Phases 2
No data
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients—1————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Medication adherenceD055118EFO_0006344————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameDIROXIMEL FUMARATE
INNdiroximel fumarate
Description
Diroximel fumarate, sold under the brand name Vumerity, is a medication used for the treatment of relapsing forms of multiple sclerosis (MS). It acts as an immunosuppressant and anti-inflammatory drug. Its most common adverse effects are flushing and gastrointestinal problems.
Classification
Small molecule
Drug class—
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
COC(=O)/C=C/C(=O)OCCN1C(=O)CCC1=O
Identifiers
PDB—
CAS-ID1577222-14-0
RxCUI—
ChEMBL IDCHEMBL3989944
ChEBI ID—
PubChem CID73330464
DrugBankDB14783
UNII IDK0N0Z40J3W (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
Vumerity - Biogen
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 143 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
1,922 adverse events reported
View more details